Privately-held Swiss drugmaker Ferring Pharmaceuticals has appointed Professor Klaus Dugi as executive vice president and chief medical officer (CMO), effective immediately.
He will be responsible for global medical affairs, quality assurance and pharmacovigilance. In addition, he will also be a member of the Ferring executive board.
Prior to this role, Prof Dugi held various leadership roles at Germany’s Boehringer Ingelheim, including vice president global medical affairs, CMO, and, most recently, managing director UK & Ireland.
“Making the industry more patient-centric has always been a top priority for Prof Dugi, and this is perfectly aligned with our company philosophy and commitment to solving unmet patient needs, particularly in the area of reproductive and maternal health,” said Michel Pettigrew, president of the executive board and chief operating officer, Ferring Pharmaceuticals.
A Professor of Medicine, with a speciality in internal medicine, Prof Dugi continues to teach medicine at Heidelberg University, Germany. He also spent four years carrying out research at the US National Institutes of Health (NIH) and has published more than 70 manuscripts in peer-reviewed journals including The Lancet and Diabetes.
Source: The Pharma Letter
The appointment makes Tuyen Ong the latest in a series of new CEO-partners hired by Flagship. Flagship Pioneering has named Tuyen Ong as CEO-partner. The new role sees the ex-Biogen […]
The COVID-19 pandemic has millennials worried—and that has them planning to buy more prescription drugs in the future, new research finds. WPP’s global media group, Mindshare, began surveying consumers in […]
AstraZeneca has received an investment of approximately $486m from the US Government to develop and supply its long-acting antibody (LAAB) cocktail, AZD7442, for Covid-19 treatment. AstraZeneca has received an investment […]